PTC Therapeutics PTCT Clearpoint Equity Investment Fvni Unrealized Gain Loss
Clearpoint Equity Investment Fvni Unrealized Gain Loss at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept ptct:ClearpointEquityInvestmentFvniUnrealizedGainLoss.
The official record: PTC Therapeutics’s 10-Q, filed November 4, 2025, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's clearpoint equity investment fvni unrealized gain loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's clearpoint equity investment fvni unrealized gain loss?
- PTC Therapeutics (PTCT) reported clearpoint equity investment fvni unrealized gain loss of $8.81M in Q3 2025.
- How has PTC Therapeutics's clearpoint equity investment fvni unrealized gain loss changed year-over-year?
- PTC Therapeutics's clearpoint equity investment fvni unrealized gain loss increased by 69.3% year-over-year, from $5.21M to $8.81M.
- What is the long-term trend for PTC Therapeutics's clearpoint equity investment fvni unrealized gain loss?
- Over 2 years (2021 to 2024), PTC Therapeutics's clearpoint equity investment fvni unrealized gain loss has grown at a 12.3% compound annual growth rate (CAGR), from -$6.09M to $7.69M.
- What does clearpoint equity investment fvni unrealized gain loss mean?
- The change in fair value of equity investments measured at fair value through net income that remains unrealized at the reporting date. It reflects market-driven fluctuations in the value of strategic equity holdings.